A study tracks how changes in the criteria over the past two-plus decades have affected treatment and outcomes.
Updates to multiple sclerosis (MS) diagnostic criteria have resulted in earlier time to diagnosis and treatment. To further examine the effects of these updates, investigators conducted a retrospective study of 1174 patients with clinically isolated syndrome (CIS) who presented with their first demyelinating event between 1994 and 2020. The cohort was divided into the following five diagnostic periods during this timeframe: Poser period (1994–2000), McDonald (2001–2004), McDonald (2005–2009), McDonald (2010–2016), and McDonald (2017–2020). Patients were then evaluated according to the diagnostic criteria used in each period.
From the Poser period to the McDonald (2017–2020) period, the proportion of CIS patients who received an MS diagnosis …
Reviewing Author
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)
DisclosuresConsultant/Advisory BoardAlexion Pharmaceuticals; Amgen; Astoria; Biogen; Bristol Myers Squibb; Celltrion; Genentech; Hoffmann-La Roche; Genzyme; EMD Serono; Immpact-Bio; Immunic Therapeutics; Kyverna; Lundbeck; Novartis; Sandoz; TG Therapeutics
Grant/Research SupportNational Institutes of Health; National Multiple Sclerosis Society; U.S. Department of Defense
Leadership Positions in Professional SocietiesConsortium of Multiple Sclerosis Centers (Treasurer)